The American Society of Clinical Oncology’s (ASCO) super-influential conference may not kick off until June 3. But you may want to pay attention to presenting companies now. That’s because this very conference is where biotech companies announce some of their clinical research data. And historically, we’ve seen biotech stocks run up going into ASCO.
Here’s what we’re watching for this year.
ASCO Stock No. 1 – Puma Biotechnology (PBYI)
Puma Biotechnology will present abstracts on neratinib.
- Abstract 1028: Neratinib + fulvestrant + trastzuzumab (N+F+T) for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial
- Abstract 4079: Targeting HER2 mutation-positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT ‘basket’ trial
ASCO Stock No. 2 – Immutep Ltd. (IMMP)
IMMP, a biotech developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, announced that new interim data from first line non-small cell lung cancer patients of the Phase II TACTI-002 trial has been selected for a prestigious Oral Presentation at the American Society of Clinical Oncology’s 2022 Annual Meeting. In addition, the Phase IIb TACTI-003 trial design will be presented in a Trial-in-Progress Poster Presentation.
- Title: A Phase II study (TACTI-002) in 1st line metastatic non-small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: updated results from a PD-L1 unselected population
Session Title: Oral Abstract Session/ Lung Cancer – Non-Small Cell Metastatic
- Title: TACTI-003: A randomized Phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous-cell carcinoma
Session Title: Poster Session/Head and Neck Cancer
ASCO Stock No. 3 – Karyopharm Therapeutics (KPTI)
KPTI announced that four abstracts highlighting selinexor clinical research have been selected for presentation, including one oral presentation, at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
Research findings to be presented include an oral presentation discussing subgroup analyses and molecular classification data from the Phase 3 SIENDO study evaluating selinexor in endometrial cancer and a poster presentation highlighting preliminary results from a Phase 1/2 study evaluating selinexor in combination with ruxolitinib in patients with treatment-naïve myelofibrosis.